![Maria Charlotte Fribert](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Maria Charlotte Fribert is the founder of Epixis SA. She is currently the Chief Executive Officer at Toleranzia AB since 2016.
Previously, she worked at AstraZeneca R&D Mölndal as a Project Director-Drug Development.
Dr. Fribert holds a doctorate degree from Université Pierre et Marie Curie.
| Sociétés | Poste | Fin |
|---|---|---|
AstraZeneca R&D Mölndal | Corporate Officer/Principal | - |
Epixis SA
 Epixis SA BiotechnologyHealth Technology Specializes in the development of advanced immuno-therapies | Fondateur | - |
| TOLERANZIA AB | Directeur Général | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 4 |
|---|---|
Université Pierre et Marie Curie
 Université Pierre et Marie Curie Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Epixis SA
Epixis SA BiotechnologyHealth Technology Specializes in the development of advanced immuno-therapies | Health Technology |
AstraZeneca R&D Mölndal | |
Toleranzia AB
 Toleranzia AB BiotechnologyHealth Technology Operates as a biotechnology company that develops drugs for the treatment of autoimmune orphan diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
